PROVECTUS BIOPHARMACEUTICALS, INC. 4
4 · PROVECTUS BIOPHARMACEUTICALS, INC. · Filed Jul 1, 2014
Insider Transaction Report
Form 4
CULPEPPER PETER R
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2014-06-28$1.25/sh+100,000$125,000→ 1,112,332 total - Exercise/Conversion
Stock Option (right to buy)
2014-06-28−100,000→ 0 totalExercise: $1.25From: 2004-06-28Exp: 2014-06-28→ Common Stock (100,000 underlying)
Holdings
- 121,000(indirect: By 401(k))
Common Stock